title: A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
abstract: Human respiratory syncytial virus (RSV), for which no clinically approved vaccine is available yet, is globally a serious pediatric pathogen of the lower respiratory tract. Several approaches have been used to develop vaccines against RSV, but none of these have been approved for use in humans. An efficient vaccine-enhancing strategy for RSV is still urgently needed. We found previously that oral SL7207/pcDNA3.1/F and intranasal FGAd/F were able to induce an effective protective immune response against RSV. The heterologous prime-boost immunization regime has been reported recently to be an efficient vaccine-enhancing strategy. Therefore, we investigated the ability of an oral SL7207/pcDNA3.1/F prime and intranasal (i.n.) FGAd/F boost regimen to generate immune responses to RSV. The SL7207/pcDNA3.1/F prime-FGAd/F boost regimen generated stronger RSV-specific humoral and mucosal immune responses in BALB/c mice than the oral SL7207/pcDNA3.1/F regimen alone, and stronger specific cellular immune responses than the i.n. FGAd/F regimen alone. Histopathological analysis showed an increased efficacy against RSV challenge by the heterologous prime-boost regimen. These results suggest that such a heterologous prime-boost strategy can enhance the efficacy of either the SL7207 or the FGAd vector regimen in generating immune responses in BALB/c mice.
authors.affiliation: College of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing 100044, China.
authors.forename: Yuan-Hui
authors.initials: YH
authors.lastname: Fu
authors.forename: Jin-Sheng
authors.initials: JS
authors.lastname: He
authors.forename: Xiao-Bo
authors.initials: XB
authors.lastname: Wang
authors.forename: Xian-Xian
authors.initials: XX
authors.lastname: Zheng
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wu
authors.forename: Can
authors.initials: C
authors.lastname: Xie
authors.forename: Mei
authors.initials: M
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.forename: Qian
authors.initials: Q
authors.lastname: Tang
authors.forename: Jing-Dong
authors.initials: JD
authors.lastname: Song
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Qu
authors.forename: Tao
authors.initials: T
authors.lastname: Hong
mesh_terms: D000256:Adenoviridae / Q000276:immunology / Q000502:physiology; D000818:Animals; D000917:Antibody Formation; D005260:Female; D005822:Genetic Vectors / Q000276:immunology / Q000502:physiology; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary / Q000379:methods*; D008168:Lung / Q000276:immunology / Q000473:pathology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D011024:Pneumonia, Viral / Q000473:pathology / Q000517:prevention & control*; D018357:Respiratory Syncytial Virus Infections / Q000473:pathology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000235:genetics / Q000276:immunology*; D012486:Salmonella typhimurium / Q000276:immunology*; D014611:Vaccination / Q000379:methods*; D014779:Virus Replication
chemical_list: D022261:Respiratory Syncytial Virus Vaccines